# Signals Article: Putative Target Q8IWL2 for Idiopathic Pulmonary Fibrosis
Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by the scarring of lung tissue, leading to a decline in lung function. The cause of IPF is unknown, and the disease has a poor prognosis with limited treatment options. The identification of novel molecular targets is critical for developing more effective therapies to improve patient outcomes.
Data-mining rationale
In a recent reanalysis effort, UniProt entry Q8IWL2 was identified as a putative target for IPF. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200235829, GDS:200240470, GDS:200222065, GDS:200209929, and GDS:200195770. Although Q8IWL2 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing Q8IWL2 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of Q8IWL2's potential as a target for IPF. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of Q8IWL2 as a target for IPF, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of IPF. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of Q8IWL2. If validated, assessing the druggability of Q8IWL2 via DGIdb and ChEMBL will be crucial for potential therapeutic development.